Skip to main content
Research

Research Impact: Enterprise and Commercial Innovation 2026 Shortlist

This award recognises the importance of commercial partnerships and commercial innovation from research.

Prof Nelya Koteyko

Professor Nelya Koteyko leads pioneering research on digital communication and inclusion through the Autistic Adults Online project, which has reshaped understanding of how autistic individuals engage in online spaces. Her work challenges deficit-based assumptions, demonstrating that differences in communication arise from platform design rather than individual limitations. Through interdisciplinary research and co-design, she has developed practical toolkits to support more inclusive digital environments. This work has significant potential impact for both technology companies and public organisations, helping to create more accessible and equitable online spaces.

Nelya Koteyko

For more information about Autistic Adults Online

Dr Patrick Cullen

Dr Patrick Cullen is a leader in translational energy research and co-founder of the spinout company Methanox, which addresses methane emissions from liquefied natural gas-powered ships. His work has identified a major gap in maritime decarbonisation and translated this insight into innovative catalytic technologies with strong commercial and environmental potential. Backed by significant investment and moving into real-world deployment, Methanox offers a scalable solution to reduce emissions across the global shipping industry. Patrick’s leadership in bridging academic research and commercial application exemplifies impactful innovation with global relevance.

Patrick Cullen

For more information about Methanox

Dr Suzanne Eldridge

Dr Suzanne Eldridge is a leading figure in translational research and entrepreneurship, serving as Co-Founder and CEO of ReFleks Ltd. Her work translates cutting-edge musculoskeletal research into innovative treatments for osteoarthritis, underpinned by a strong intellectual property portfolio and high-impact academic outputs. ReFleks has achieved national recognition and is positioned to deliver transformative, disease-modifying therapies. Alongside her commercial leadership, Suzanne remains deeply engaged in academia and mentorship, supporting emerging researchers and championing diversity in enterprise through initiatives such as the Female Founders Forum.

Suzanne Eldridge

For more information about ReFleks Ltd

Back to top